Mercy Health System Corporation

11/16/2026 | Press release | Archived content

Mercyhealth Participates in International Clinical Trial Exploring New Approach to Stroke Prevention in Patients with Atrial Fibrillation

Mercyhealth is participating in the LAAOS-4 clinical trial, an international research study evaluating whether closing the left atrial appendage with the WATCHMANâ„¢ device, in addition to blood-thinner medication, may provide greater protection against stroke than blood-thinner medication alone in certain patients with atrial fibrillation (AFib).

Atrial fibrillation is a common heart rhythm condition that can increase the risk of blood clots and stroke. Blood clots can form in an area of the heart called the left atrial appendage and may travel to the brain, potentially causing a stroke.

Through its participation in LAAOS-4, Mercyhealth is helping contribute to research evaluating additional approaches to stroke prevention for patients living with AFib who are at high risk for stroke.

"This is an exciting time for our research department as we continue to grow the number and scope of clinical trials available to our patients," said Katy Phetteplace, Manager of Cardiology and Neurology Research Services at Mercyhealth. "Participating in studies like LAAOS-4 allows us to expand access to innovative research opportunities within our community while strengthening Mercyhealth's role in advancing cardiovascular research. We are excited about what this continued growth means for our patients, our providers and the future of our research program." "Clinical research gives our physicians an opportunity to bring innovative therapies and important research opportunities to patients in our communities," said Dr. Imdad Ahmed, Director of Mercyhealth Arrhythmia Center and Patient Safety and Quality. "Our participation in LAAOS-4 reflects Mercyhealth's commitment to advancing cardiovascular care while contributing to research that may help inform future treatment options for patients with atrial fibrillation."

The LAAOS-4 study is evaluating two treatment approaches. Participants are randomly assigned to either receive the WATCHMAN implant in addition to continuing blood-thinner medication or to continue blood-thinner medication without implantation of the device.

The WATCHMAN implant is designed to close the left atrial appendage, an area of the heart where blood clots can form in people with AFib. The implant is delivered through a minimally invasive procedure using a catheter inserted through a vein in the upper leg.

For more information on Mercyhealth's cardiovascular clinical trials, visit mercyhealthsystem.org/services/cardiology/clinical-trials or call (608) 756-6532.

About clinical research at Mercyhealth

Mercyhealth is committed to advancing medical knowledge and expanding opportunities for patients to participate in clinical research. Through its cardiovascular clinical research program, Mercyhealth physicians and research teams participate in studies evaluating new treatments, devices and approaches to cardiovascular care.

Mercyhealth also offers clinical trials in neurology and cancer care.

Mercy Health System Corporation published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 18, 2026 at 16:35 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]